Treating OCD: what to do when first-line therapies fail
David Castle, Peter Bosanac, Susan Rossell
Australasian Psychiatry | SAGE PUBLICATIONS LTD | Published : 2015
David Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca and Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira and Servier; and is a current Advisory Board Member for Lu AA21004 (Lundbeck); Varenicline (Pfizer); Asenapine (Lundbeck); Bitopertin (Roche); Aripiprazole LAI (Lundbeck); and Lisdexamfetamine (Shire). He has no stocks nor shares in any pharmaceutical company.